Baird's Investment Banking Group is pleased to announce the following transaction:

October 2021
MiNK Therapeutics, Inc.
Initial Public Offering
Technology & Services
Baird served as co-manager on this offering
$40.000 Million

MiNK Therapeutics, Inc. (“MiNK”) (NASDAQ-GM: INKT) recently completed an initial public offering of 3,333,334 shares of its common stock at a public offering price of $12.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $40 million.

MiNK is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. MiNK Therapeutics, Inc. is headquartered in New York, New York.

For additional information about this transaction, please contact:

Derrick Li +1-516-606-6763
Lance Lange +1-414-765-7079
Michael Kim +1-312-609-4482
Matt Gailey +1-414-765-1458